February 4, 2022

VDH COVID-19 Therapeutics Bi-Weekly Update

Total Allocations to Monoclonal Antibody Administration Sites (September 27, 2021 - February 3, 2022):

<table>
<thead>
<tr>
<th>Monoclonal Antibody</th>
<th>Central</th>
<th>Eastern</th>
<th>Northern</th>
<th>Northwest</th>
<th>Southwest</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bam with Ete</td>
<td>1054</td>
<td>790</td>
<td>353</td>
<td>1450</td>
<td>1923</td>
<td>5570</td>
</tr>
<tr>
<td>Ete Solo</td>
<td>370</td>
<td>254</td>
<td>710</td>
<td>500</td>
<td>1311</td>
<td>3145</td>
</tr>
<tr>
<td>REGEN – COV</td>
<td>3535</td>
<td>2187</td>
<td>2945</td>
<td>4905</td>
<td>7391</td>
<td>20963</td>
</tr>
<tr>
<td>Sotrovimab</td>
<td>1242</td>
<td>1350</td>
<td>2028</td>
<td>1668</td>
<td>1524</td>
<td>7812</td>
</tr>
<tr>
<td>Evusheld</td>
<td>2160</td>
<td>912</td>
<td>960</td>
<td>1704</td>
<td>696</td>
<td>6432</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>8361</strong></td>
<td><strong>5493</strong></td>
<td><strong>6997</strong></td>
<td><strong>10227</strong></td>
<td><strong>12845</strong></td>
<td><strong>43923</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Oral Antiviral</th>
<th>Central</th>
<th>Eastern</th>
<th>Northern</th>
<th>Northwest</th>
<th>Southwest</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paxlovid</td>
<td>1120</td>
<td>760</td>
<td>780</td>
<td>1080</td>
<td>1440</td>
<td>5180</td>
</tr>
<tr>
<td>Molnupiravir</td>
<td>4100</td>
<td>4000</td>
<td>2640</td>
<td>4220</td>
<td>5220</td>
<td>20180</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>5220</strong></td>
<td><strong>4760</strong></td>
<td><strong>3420</strong></td>
<td><strong>5300</strong></td>
<td><strong>6660</strong></td>
<td><strong>25360</strong></td>
</tr>
</tbody>
</table>

mAb and Oral Antiviral Distribution Maps

Provider Locations (Monoclonal Antibodies)

Provider Locations (Oral Antivirals)

**Reporting Therapeutics Usage & Inventory**

- Sites that do not comply with the reporting requirements by 2/22/2022 will NOT receive additional allocations of therapeutics
- Reporting of doses used last week and on-hand to the U.S. Healthcare COVID-19 Portal (i.e., TeleTracking) is required **weekly on Wednesdays by 11:59PM ET** for Bam/Ete, REGEN-COV, and Sotrovimab
  - VDH has published a job aid for reporting into the U.S. Healthcare COVID-19 Portal, which can be accessed [here](#)
- Reporting of doses used and on-hand to HPoP is required **daily by 11:59 PM ET** for Evusheld, Paxlovid, and Molnupiravir
  - VDH is currently developing a job aid for reporting into the Health Partner Order Portal (HPoP)

**Bam/Ete and REGEN-COV Monoclonal Antibody Information (HHS Update 1/26/2022)**

- The return of Bam/Ete and REGEN-COV is not recommended; any returned product has to be destroyed
- The COVID-19 environment remains dynamic
Existing monoclonal antibody products (e.g., Bam/Ete, REGEN-COV) may be effective against future variants

**Therapeutics Storage (HHS Update 1/26/2022)**

- If you have storage concerns or challenges:
  - Consider transferring products to another location/site in your region or health system
  - If your facility does not have the appropriate storage space and you would like to transfer product, please contact covid19therapeutics@vdh.virginia.gov
- If product must be returned:
  - For Bam/Ete, see The Lilly Return Goods Procedure; detailed guidance can be found at: https://www.lillytrade.com/
  - For REGEN-COV, call 844-734-6643
  - Note: Reconstituted (diluted) product SHOULD NOT be returned and should be treated as waste per your facility’s SOP

**Reminder: CMS Code for Outpatient Intravenous Veklury (Remdesivir) Use**

- Following a recent statement from the National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel regarding therapies for COVID-19 Omicron variant, CMS created **HCPCS code J0248** for the antiviral medication Veklury (Remdesivir) when administered in outpatient setting
- Medicare Administrative Contractors (MACs) determine Medicare coverage when no national coverage determination exists, including when providers use FDA-approved drugs for indications other than what is on the approved label
- MACs will determine Medicare coverage for HCPCS code J0248 for Veklury (Remdesivir) administered in the outpatient setting
- See CMS COVID-19 Provider Toolkit for additional information
- Reimbursement information is still pending with the Virginia MACs
  - The VDH COVID-19 Therapeutics team will update these guidelines as soon as more information is available

**Updates to the VDH COVID-19 Treatment Locator Tool**

- Please find the locator tool here: COVID-19 Treatment Locator
- If you are not listed on the Locator Tool and provide appointments to the public, please email covid19therapeutics@vdh.virginia.gov and your information will be added

**Upcoming COVID-19 Therapeutics Webinar Details**

- Registration links:
  - Wednesday, 02/09/2022 from 12-1PM
  - Wednesday, 02/16/2022 from 12-1PM
  - Wednesday, 02/23/2022 from 12-1PM